Audit: QRS - Psilocybin for Health & Longevity
Audit conducted on 21/08/2026 17:28 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every item traced to the ER: gates to Key Interactions & Contraindications, benefit/risk tiers to the ER headings, markers/targets to the ER monitoring table, protocol cells to Therapeutic Protocol. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious phrasing carried over, e.g. marker_3_why “proposed but not shown to lower” (ER line 418) and marker_8/9 targets “No established target” (ER lines 423-424). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Thresholds and absolutes preserved unchanged: “at or above 140/90 mmHg despite treatment”, “Corrected QT above 450 ms (men) or 470 ms (women)”, “Pregnancy and breastfeeding”. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Nothing from Benefit-Modifying Factors or Risk-Modifying Factors is surfaced in the gates; all gate items come from the ER interactions/contraindications section. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names, or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | Griffiths/Johnson, Bogenschutz/Ross, Schindler, COMPASS and PEX010 attributions in the ER are all omitted; none added. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s sceptical-but-fair register, including the blinding and funding caveats carried into [at_a_glance]. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and objective, with concrete numbers in the protocol, gates, and monitoring table. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Descriptive throughout; describes what trials and protocols do rather than instructing. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No prescriptive or advisory constructions; the footer disclaimer is unchanged template text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “advised”, or “should” constructions in the QRS’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file (verified by search). |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain wording used where possible; the remaining technical terms (Child-Pugh, NYHA, QTc, hs-CRP, eGFR) are necessary identifiers taken verbatim from the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every cell is a condensed phrase; gate and tier items are bare facts with no rationale. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no direct address to the reader. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framed for a proactive, risk-aware reader: decision gates, monitoring targets, and protocol parameters are foregrounded. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Presents an effortful protocol (supervised six-to-eight-hour sessions, antidepressant taper, two-to-four-week baseline work) without softening. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes willingness to undertake screening, monitoring, and supervised sessions; not written for a general audience. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The healthy-user signal is handled explicitly — [at_a_glance] states the slowed-aging claim rests on cells and mice, and geroprotection sits in the Speculative benefit tier. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not appear; the sheet uses “aging brain” and “slowed-aging”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terminology throughout (e.g. “Monoamine oxidase inhibitors”, “valve regurgitation”, “epigenetic age”). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All fixed strings present and unmodified: “Protocol” (line 444), “Time to effect” (482), “Benefits” (525), “Risk & Side Effects” (590), “Monitoring” (614), “Qualitative Assessment” (733), “Contraindications” (549), “Key Interactions” (567), High/Medium/Low/Speculative in both tiered cards, and Marker/Target/Why (618-620). |
| 3.2 | All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS. | 🟢 | 68 data-qrs-var spans present and complete: header (4), at_a_glance, action_1-3 x3, time_1-3 x3, benefits x4, stop/caution, risks x4, marker_1-9 x3, monitoring_cadence, qualitative_item_1-7. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Untouched template spans remain as shipped, including , and (lines 423, 426, 438). |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; every QRS section had ER content to draw on. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | ER bold labels reused verbatim: “Standard supported-session model”, “Two-dose model”, “Time of day” (ER lines 358, 359, 363), and the interaction/contraindication labels in both gates. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label is invented where the ER supplies one; biomarker row labels match the ER table names exactly. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji anywhere in the file; the ER’s 🟩/🟥/🟨 tier markers and ⚠️ Conflicted flags are stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Each section is condensed to bare facts — tier lines carry ER headings only, gate items carry no rationale, and Why cells are single clauses — rather than extended with ER elaboration. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens at line 2, immediately after <!doctype html> and before any other comment or markup. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by — at lines 3 and 13; the leading “QRS — Metadata” text sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Wholly inside an HTML comment; no element on the sheet repeats any of the values. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed and unquoted except duration: “00:03”, which contains a colon and therefore requires quoting. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: psilocybin_2026-0821-1449_Opus_ER.md (line 4). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 (line 5), matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0821-1711 (line 6), correct YYYY-MMDD-HHMM format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (line 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 (line 8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number, no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: psilocybin_2026-0821-1449_Opus_QRS.html (line 9), matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Confirmed again across all nine keys; only duration carries quotes, as required by its colon. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22 reads “Psilocybin for Health & Longevity - Quick Reference Sheet”, matching canonical_topic plus the fixed suffix, with the ampersand entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | [header_topic] is “Psilocybin for Health & Longevity” (line 417), matching canonical_topic. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 08/21/2026 (line 421) is qrs_creation_date 2026-0821 in MM/DD/YYYY. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5” (line 425) matches qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the template subline; no badge, alternate-names line, version stamp, or audit date. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (lines 452-456): strongest signal, thinner signals, harms, the two structural weaknesses, and the aging caveat. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words, within the 60-word cap. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct ER passage — ER line 452 (mood shift, strongest/thinner evidence, harms), line 454 (blinding, funding), line 456 (cells and mice). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or technical classifications; uses “this mushroom compound”, “serious-illness distress”, “funders often have a stake”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes, or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, relative risks, or statistical results. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items trace to the ER Key Interactions & Contraindications section (ER lines 319-339). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Covers the two ER absolute contraindications (MAOIs, lithium) plus all eight entries of “Populations who should avoid Psilocybin”; lithium is folded into the ER’s own “Seizure disorder, or current lithium therapy” bullet. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Nine discrete <li> elements inside the [stop_items] span (lines 552-562). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No trailing rationale — the ER’s “given hepatic clearance of psilocin” and the Child-Pugh gloss are stripped; no dash clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds and staging preserved: 140/90 mmHg, infarction within 6 months, NYHA III–IV, moderate-or-greater valve regurgitation, QT 450/470 ms, Child-Pugh Class B or C, MAOI drug examples. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication bullets. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does identify populations that must avoid the intervention. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no population that should avoid the intervention –> | N/A | The section is not empty, so no absence comment is required. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items trace to the ER’s caution bullets (ER lines 321-328). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Carries the eight caution-level ER bullets and correctly excludes the MAOI and lithium bullets already placed in Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight discrete <li> elements inside the [caution_items] span (lines 570-580). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanistic rationale and mitigation clauses from the ER bullets are all stripped; no dash clauses remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named example drugs preserved for every item — escitalopram/sertraline/venlafaxine, amitriptyline/imipramine, risperidone/olanzapine/quetiapine, dextromethorphan/diphenhydramine, the four serotonergic supplements, Syrian rue/harmala alkaloids, amphetamine/methylphenidate/caffeine, cannabis/alcohol/other psychedelics. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interaction bullets. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER does identify interactions that change how the intervention is used. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no interaction that changes how the intervention is used –> | N/A | The section is not empty, so no absence comment is required. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol section (ER lines 358, 359, 363). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Covers the two named delivery models that carry the trial evidence plus session timing — the three parameters a reader would have to fix to act. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well more than three actionable implementation aspects, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry ER-derived content, e.g. action_1_sub’s synthetic psilocybin, eyeshades and music, two monitors for six to eight hours (ER line 358). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Covers the depression, heavy-drinking, and well-being/openness time courses — the only three the ER quantifies (ER lines 165, 193, 394). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High (depressive symptoms) → Medium (heavy drinking) → Low (well-being and trait openness), matching the ER benefit tiers. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields carry ER-derived content; e.g. time_3_sub’s “only after a complete mystical-type experience” comes from ER line 193. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the row is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All eleven items map one-to-one onto the ER Expected Benefits headings (ER lines 155-219). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (lines 527-542). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are ER headings reduced to bare facts; no effect sizes, magnitudes, or mechanisms carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives; the ER’s ⚠️ Conflicted marker on the depression heading is also dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eleven items map one-to-one onto the ER Potential Risks & Side Effects headings (ER lines 240-304). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (lines 592-608). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are ER headings reduced to bare facts; relative risks and confidence intervals are all omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | Parenthetical content stripped — ER’s “Cardiac Valvulopathy (Damage to a Heart Valve)” becomes “Cardiac valvulopathy”. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table and cadence both derive from the ER Monitoring Protocol & Defining Success section (ER lines 412-424). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarkers listed with targets verbatim: resting blood pressure, QTc, hs-CRP, ALT, eGFR, PHQ-9, GAD-7, trait openness, epigenetic age. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | [monitoring_cadence] (line 727) carries the full ER cadence: 2-4 week baseline, in-session vitals at 30/60/90/120 minutes, scales at day 2, day 8, week 3, week 6 then quarterly through year 1, annual bloods, echocardiogram only after frequent sustained low-dose exposure. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the qualitative marker list in the ER Monitoring Protocol & Defining Success section (ER lines 428-434). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All seven ER qualitative markers listed verbatim across qualitative_item_1 to qualitative_item_7. |
Issues 21/08/2026 17:28
Pass rate 100.00%. No issues found.
Issues 21/08/2026 17:17
- 4.5 — Sheet overflows one A4 page: Total visible text is 841 words and the sheet renders to roughly two A4 pages; the Monitoring “Why” column (lines 637-737), [monitoring_cadence] (lines 743-748, 421 characters) and the protocol/time [sub] cells (lines 454-455, 466-467, 478-479, 496-497, 508-509, 520-521) carry ER sentences verbatim instead of being condensed to the per-section budget.
Fixes 21/08/2026 17:17
- 4.5 — Monitoring “Why” column condensed: All nine
marker_#_whycells were reduced from verbatim ER sentences to phrase-length entries (e.g. “Psilocybin transiently raises it; a high starting point makes the rise consequential” → “Psilocybin transiently raises it; a high baseline matters”), collapsing most table rows from two lines to one. - 4.5 — Sentence-length marker targets shortened:
marker_8_targetandmarker_9_targetwere trimmed to “No established target; track change from own pre-session score” and “No established target; track change from own baseline, one provider”, keeping the ER’s “No established target” phrasing. - 4.5 — Monitoring cadence compressed:
monitoring_cadencewas cut from 421 to 348 characters by tightening the wording (“in the two to four weeks before” → “2–4 weeks before”, “every 3 months through the first year” → “quarterly through year 1”) without dropping any monitoring step. - 4.5 — Protocol and time-to-effect subs condensed:
action_1_sub,action_3_sub,time_1_subandtime_3_subwere shortened from full ER sentences to compact clauses, dropping one wrapped line from each protocol-grid row. - 4.5 — Decision-gate items trimmed: Four contraindications and two key interactions were tightened (e.g. “Uncontrolled hypertension (resting blood pressure at or above 140/90 mmHg despite treatment)” → “Uncontrolled hypertension (at or above 140/90 mmHg despite treatment)”), with every threshold, time window, severity class and named example drug retained.